Secondary SBP Prophylaxis is associated with a higher rate of non-SBP infections in Two US-based National Cirrhosis Cohorts.|https://dx.doi.org/10.14309/ctg.0000000000000837
Anatomic Drivers of J-Sign Presence and Severity: If There Is a Jump, Look for a Bump.|https://dx.doi.org/10.1177/03635465251322788
Efficacy and safety of early antibiotic de-escalation in febrile neutropenia for patients with hematologic malignancy: a systematic review and meta-analysis.|https://dx.doi.org/10.1128/aac.01597-24
Thrombosis Secondary to Intravenous Dicyclomine Administration: A Case Report and Literature Review.|https://dx.doi.org/10.1177/08971900251326808
Fecal microbiota transplantation in a patient hospitalized in the intensive care unit - Case report.|https://dx.doi.org/10.1016/j.heliyon.2025.e42793
Impact of Clostridioides difficile Infection on Clinical Outcomes in Hospitalized IBD Patients and the Role of Fecal Microbiota Transplantation: A Retrospective Cohort Study.|https://dx.doi.org/10.1002/kjm2.70002
Risk Factors for Antibiotic Exposure Post-Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection: A Prospective Multicenter Observational Study.|https://dx.doi.org/10.1093/ofid/ofaf130
Molecular clock complexities of Clostridioides difficile.|https://dx.doi.org/10.1016/j.anaerobe.2025.102953
A "movement" worth making: why and how Transfusion Services can play a role in Fecal Microbiota Transplant programs.|https://dx.doi.org/10.2450/BloodTransfus.929
Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection.|https://dx.doi.org/10.1007/s40121-025-01130-5
Australian Paediatric Surveillance Unit (APSU) Annual Surveillance Report 2023.|https://dx.doi.org/10.33321/cdi.2025.49.019
Repurposing thioridazine as a potential CD2068 inhibitor to mitigate antibiotic resistance in Clostridioides difficile infection.|https://dx.doi.org/10.1016/j.csbj.2025.02.036
[Challenges and progress in in the clinical application of fecal microbiota transplantation].|https://dx.doi.org/10.3760/cma.j.cn441530-20241224-00420
Clostridium Butyricum Miyairi Bacteriocin Treatment for Clostridioides difficile Infections with Clinical Isolates: Insights from In Vitro, Ex Vivo, and Mouse Model Studies.|https://dx.doi.org/10.1016/j.jgar.2025.03.007
Impact of Fecal Microbiota Transplant Formulations, Storage Conditions, and Duration on Bacterial Viability, Functionality, and Clinical Outcomes in Patients with Recurrent Clostridioides difficile Infection.|https://dx.doi.org/10.3390/microorganisms13030587
Exploring the Immunological Role of the Microbial Composition of the Appendix and the Associated Risks of Appendectomies.|https://dx.doi.org/10.3390/jpm15030112
Insights into the Interaction Between Clostridioides difficile and the Gut Microbiome.|https://dx.doi.org/10.3390/jpm15030094
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases.|https://dx.doi.org/10.1080/14712598.2025.2484303
Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan.|https://dx.doi.org/10.3390/antibiotics14030228
Fecal microbiota transplantation to decolonize vancomycin-resistant Enterococcus: A pilot study to evaluate safety and clinical outcome.|https://dx.doi.org/10.1016/j.jgar.2025.03.011
